Novartis (NVS) Enhances Forecast Following Ianalumab Trial Success and Leqvio Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 31 2025
0mins
Source: Yahoo Finance
Novartis AG Overview
- Company Profile: Novartis AG (NYSE: NVS) is a leading multinational pharmaceutical company based in Switzerland, dedicated to the research, development, manufacturing, and marketing of innovative medicines. The company employs over 109,000 individuals from more than 140 nationalities globally.
Recent Developments
Ianalumab Trial Results: On August 11, 2025, Novartis announced positive Phase III trial results for ianalumab, a novel monoclonal antibody. The drug successfully met its primary endpoints in trials for Sjögren’s disease and primary immune thrombocytopenia (ITP), positioning it as a potential first targeted treatment for Sjögren’s, a chronic autoimmune disorder with significant unmet needs.
Leqvio FDA Approval: On July 31, 2025, the FDA approved a label update for Leqvio, a cholesterol-lowering medication, allowing it to be used as a first-line monotherapy. This update enhances its utility and addresses patient adherence challenges in cholesterol management, a key risk factor for heart disease.
Market Response
Stock Ratings: Following these positive developments, Novartis received a Buy rating from Kepler Capital and Deutsche Bank, while UBS maintained a Hold rating. The stock continues to attract institutional interest, with 34 hedge funds holding stakes in the company.
Dividend Information: Novartis offers an annual dividend of $3.99 per share, making it one of the best annual dividend stocks according to hedge funds.
Investment Considerations
- Comparative Analysis: While Novartis shows potential as an investment, the article suggests that certain AI stocks may offer greater upside potential and lower downside risk. A report on undervalued AI stocks is mentioned for those interested in alternative investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 153.920
Low
112.00
Averages
127.75
High
143.00
Current: 153.920
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Switzerland's Population Cap Referendum Sparks Controversy
- Population Growth Trend: As of 2025, Switzerland's population exceeded 9.1 million, marking a 10% increase over the past decade, with the notable shift of having more individuals over 65 than under 20, raising concerns about public service and housing pressures.
- Immigration Policy Impact: Should the referendum pass, Switzerland will implement measures to cap population growth, tightening immigration systems and potentially ending the free movement agreement with the EU, which could adversely affect economic competitiveness.
- Business Opposition: The Swiss business community, including firms like Nestle and UBS, warns that significant immigration restrictions would weaken innovation and economic growth, complicating the attraction of international talent and potentially shifting investment decisions.
- Poll Results: A recent poll indicates that 52% of respondents oppose the population cap proposal while 45% support it, reflecting public division over immigration policy and concerns regarding its future economic implications.
See More
Novartis RNA Therapy Del-Brax Shows Success in Muscular Dystrophy Trial
- Clinical Trial Success: Novartis's RNA therapy del-brax has succeeded in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy, marking a significant breakthrough for the company in the rare neuromuscular disease space.
- Biomarker Improvement: The trial results indicate that del-brax met primary and key secondary endpoints by showing reductions in biomarkers such as KHDC1L and creatine kinase, demonstrating its effectiveness in reducing muscle damage.
- Potential Market Leader: Novartis suggests that del-brax could become the first disease-modifying treatment for FSHD, further solidifying its leadership position in the muscular dystrophy treatment market and likely attracting increased investor interest.
- Follow-Up Trial Plans: Currently, Novartis is enrolling patients for the Phase 3 trial of del-brax and plans to share the latest results with regulators, showcasing the company's commitment to advancing innovative drug development.
See More
Novartis Expands Deal with Orionis for Molecular Glue Drugs
- Partnership Expansion: Novartis has expanded its multiyear partnership with Orionis Biosciences, leveraging Orionis' Allo-Glue platform and AI drug discovery capabilities to advance molecular glue medicines, showcasing Novartis' strategic foresight in biopharmaceuticals.
- Financial Commitment: Novartis will provide Orionis with $40 million upfront, along with milestone payments potentially reaching $1.4 billion and tiered royalties on net sales, significantly enhancing Orionis' research and development capabilities.
- Positive Market Reaction: The announcement of this deal has boosted the stock prices of Monte Rosa Therapeutics, Kymera Therapeutics, and Nurix Therapeutics, indicating a rising market interest and investment enthusiasm for molecular glue technology.
- Industry Trend: The pharmaceutical industry is increasingly focusing on molecular glue technology, and Novartis' initiative not only strengthens its competitive position in this field but may also lead to new directions in drug development, particularly for treating major diseases like cancer.
See More
Update: US Equity Futures Rise Pre-Bell After US Says Strikes Completed Against Iran
See More
Performance Analysis of iShares International ETFs
- Strong Performance: As of June 7, the iShares Core MSCI Total International Stock ETF (IXUS) achieved a total return of 25.8% over the past year, slightly outperforming the S&P 500 index, indicating its competitive edge in the international market.
- Dividend Yield Comparison: The iShares Core MSCI EAFE ETF (IEFA) offers a 12-month dividend yield of 3.3%, while IXUS provides a yield of 2.9%; both are lower than the S&P 500's P/E ratio of 31.83, suggesting that international stocks may have more room for growth.
- Portfolio Diversity: IXUS holds over 4,300 stocks across various markets, while IEFA focuses on developed markets with about 2,600 stocks, making IXUS more attractive for long-term investors despite potentially higher volatility in the short term.
- Sector Allocation Differences: IXUS allocates 21% of its assets to tech stocks compared to 11.3% for IEFA, which enhances IXUS's potential in emerging fields like AI but also increases exposure to risks associated with downturns in U.S. tech stocks.
See More
Analysis of Growth Potential in International ETFs
- Diversification Advantage: The iShares Core MSCI Total International Stock ETF (IXUS) holds over 4,000 stocks and has achieved a total return of 25.8% over the past year, slightly outperforming the S&P 500, indicating its strong performance in global markets and suitability for investors seeking diversification.
- Cost and Yield Comparison: Both ETFs have an expense ratio of 0.07%, with IXUS offering a dividend yield of 2.9% compared to 3.3% for the iShares Core MSCI EAFE ETF (IEFA), suggesting that IEFA may be more appealing for investors focused on stable cash flow.
- Sector Allocation Differences: IXUS allocates 21.8% of its assets to the information technology sector, reflecting a preference for tech stocks, while IEFA has higher allocations in financials and industrials at 22.6% and 19.7%, respectively, which may provide more defensiveness during market volatility.
- Market Risks and Opportunities: Although IXUS has slightly outperformed over the past decade, its exposure to emerging markets may lead to higher short-term volatility, prompting investors to weigh risks against potential returns to determine the ETF that best aligns with their investment goals.
See More
Switzerland's Population Cap Referendum Sparks Controversy
- Population Growth Trend: As of 2025, Switzerland's population exceeded 9.1 million, marking a 10% increase over the past decade, with the notable shift of having more individuals over 65 than under 20, raising concerns about public service and housing pressures.
- Immigration Policy Impact: Should the referendum pass, Switzerland will implement measures to cap population growth, tightening immigration systems and potentially ending the free movement agreement with the EU, which could adversely affect economic competitiveness.
- Business Opposition: The Swiss business community, including firms like Nestle and UBS, warns that significant immigration restrictions would weaken innovation and economic growth, complicating the attraction of international talent and potentially shifting investment decisions.
- Poll Results: A recent poll indicates that 52% of respondents oppose the population cap proposal while 45% support it, reflecting public division over immigration policy and concerns regarding its future economic implications.
See More
Novartis RNA Therapy Del-Brax Shows Success in Muscular Dystrophy Trial
- Clinical Trial Success: Novartis's RNA therapy del-brax has succeeded in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy, marking a significant breakthrough for the company in the rare neuromuscular disease space.
- Biomarker Improvement: The trial results indicate that del-brax met primary and key secondary endpoints by showing reductions in biomarkers such as KHDC1L and creatine kinase, demonstrating its effectiveness in reducing muscle damage.
- Potential Market Leader: Novartis suggests that del-brax could become the first disease-modifying treatment for FSHD, further solidifying its leadership position in the muscular dystrophy treatment market and likely attracting increased investor interest.
- Follow-Up Trial Plans: Currently, Novartis is enrolling patients for the Phase 3 trial of del-brax and plans to share the latest results with regulators, showcasing the company's commitment to advancing innovative drug development.
See More
Novartis Expands Deal with Orionis for Molecular Glue Drugs
- Partnership Expansion: Novartis has expanded its multiyear partnership with Orionis Biosciences, leveraging Orionis' Allo-Glue platform and AI drug discovery capabilities to advance molecular glue medicines, showcasing Novartis' strategic foresight in biopharmaceuticals.
- Financial Commitment: Novartis will provide Orionis with $40 million upfront, along with milestone payments potentially reaching $1.4 billion and tiered royalties on net sales, significantly enhancing Orionis' research and development capabilities.
- Positive Market Reaction: The announcement of this deal has boosted the stock prices of Monte Rosa Therapeutics, Kymera Therapeutics, and Nurix Therapeutics, indicating a rising market interest and investment enthusiasm for molecular glue technology.
- Industry Trend: The pharmaceutical industry is increasingly focusing on molecular glue technology, and Novartis' initiative not only strengthens its competitive position in this field but may also lead to new directions in drug development, particularly for treating major diseases like cancer.
See More
Update: US Equity Futures Rise Pre-Bell After US Says Strikes Completed Against Iran
See More
Performance Analysis of iShares International ETFs
- Strong Performance: As of June 7, the iShares Core MSCI Total International Stock ETF (IXUS) achieved a total return of 25.8% over the past year, slightly outperforming the S&P 500 index, indicating its competitive edge in the international market.
- Dividend Yield Comparison: The iShares Core MSCI EAFE ETF (IEFA) offers a 12-month dividend yield of 3.3%, while IXUS provides a yield of 2.9%; both are lower than the S&P 500's P/E ratio of 31.83, suggesting that international stocks may have more room for growth.
- Portfolio Diversity: IXUS holds over 4,300 stocks across various markets, while IEFA focuses on developed markets with about 2,600 stocks, making IXUS more attractive for long-term investors despite potentially higher volatility in the short term.
- Sector Allocation Differences: IXUS allocates 21% of its assets to tech stocks compared to 11.3% for IEFA, which enhances IXUS's potential in emerging fields like AI but also increases exposure to risks associated with downturns in U.S. tech stocks.
See More
Analysis of Growth Potential in International ETFs
- Diversification Advantage: The iShares Core MSCI Total International Stock ETF (IXUS) holds over 4,000 stocks and has achieved a total return of 25.8% over the past year, slightly outperforming the S&P 500, indicating its strong performance in global markets and suitability for investors seeking diversification.
- Cost and Yield Comparison: Both ETFs have an expense ratio of 0.07%, with IXUS offering a dividend yield of 2.9% compared to 3.3% for the iShares Core MSCI EAFE ETF (IEFA), suggesting that IEFA may be more appealing for investors focused on stable cash flow.
- Sector Allocation Differences: IXUS allocates 21.8% of its assets to the information technology sector, reflecting a preference for tech stocks, while IEFA has higher allocations in financials and industrials at 22.6% and 19.7%, respectively, which may provide more defensiveness during market volatility.
- Market Risks and Opportunities: Although IXUS has slightly outperformed over the past decade, its exposure to emerging markets may lead to higher short-term volatility, prompting investors to weigh risks against potential returns to determine the ETF that best aligns with their investment goals.
See More
